Pharmacokinetic (PK) Evaluation of Nalmefene Formulations
Completed · Phase 1
Conditions studied: Opioid Overdose
In brief
This study is designed to characterize the PK of nalmefene following IV bolus and IM injections using nalmefene 0.5 mg (0.94% MgCl2) and IV bolus of 0.5 mg nalmefene hydrochloride injection in healthy subjects.
Key facts
- Study ID
- NCT07543276
- Run by
- Knoa Pharma LLC
- People needed
- 13
- Starts
- 2026-02-06
- Expected to finish
- 2026-04-03
- Last updated by the study team
- 2026-06-05
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
Where it is running
- Ohio Clinical Trials — Columbus, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.